Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

As rivals eye ‘unjustified royalties,’ Pfizer partner sues to defend COVID-19 shot Comirnaty

Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the New York pharma's partners says rival companies are...
23 March 2022 Regional News Comirnaty | COVID-19
Continue Reading →
Volume 13 Issue 5

Considerations for Clinical Trial Design Involving Radiotherapy

Radiation therapy has been used for many years as an effective form of treatment against many cancer types, yet it remains less well researched and utilised than othe...
18 October 2021 Volume 13 Issue 5 cancer | clinical trial
Continue Reading →
Europe

Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint

The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost red...
27 June 2018 Europe clinical | DMD
Continue Reading →
Europe

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Polyamine depletion therapy represents a unique cancer immunotherapy approach Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advanc...
20 June 2018 Europe Aminex | clinical
Continue Reading →
Europe

Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy Orchard’s fourth Rare Pediatric Disease Designation for autologous ex vivo gene therapy.

Orchard Therapeutics, a leading commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today a...
9 May 2018 Europe designation | FDA
Continue Reading →
Europe

Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy – effective against the WHO Critical Priority Carbapenem resistant bacterial pathogens

The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priori...
19 April 2018 Europe clinical | Helperby
Continue Reading →
Europe

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has init...
11 April 2018 Europe | Uncategorized clinical | EBV
Continue Reading →
Europe

Shield Therapeutics 2017 Loss Widens On Clinical Trials, Higher Costs

Shield Therapeutics PLC on Wednesday reported significantly widened loss for 2017, as it progresses on Feraccru product study and commercialisation. The specialty pha...
11 April 2018 Europe 2017 | clinical
Continue Reading →
news

Domain Therapeutics’ innovative business model gains validation through Prexton Therapeutics’ acquisition by Lundbeck for up to $1.1 billion

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biote...
21 March 2018 news business | Domain
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte